Real-world data on adult AML with FLT3-ITD mutation from the Thai acute leukemia working group
2
Issued Date
2025-01-01
Resource Type
eISSN
2234943X
Scopus ID
2-s2.0-105015751965
Journal Title
Frontiers in Oncology
Volume
15
Rights Holder(s)
SCOPUS
Bibliographic Citation
Frontiers in Oncology Vol.15 (2025)
Suggested Citation
Rattanathammethee T., Rattarittamrong E., Wanitpongpun C., Kungwankiattichai S., Owattanapanich W., Chanswangphuwana C., Polprasert C., Piyajaroenkij T., Niparuck P., Saengboon S., Limvorapitak W., Silpsamrit P., Prayongratana K., Sriswasdi C., Julamanee J., Saelue P., Sasakul A., Jit-ueakul D., Nakhakes C., Tantiworawit A. Real-world data on adult AML with FLT3-ITD mutation from the Thai acute leukemia working group. Frontiers in Oncology Vol.15 (2025). doi:10.3389/fonc.2025.1606943 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/112123
Title
Real-world data on adult AML with FLT3-ITD mutation from the Thai acute leukemia working group
Author(s)
Rattanathammethee T.
Rattarittamrong E.
Wanitpongpun C.
Kungwankiattichai S.
Owattanapanich W.
Chanswangphuwana C.
Polprasert C.
Piyajaroenkij T.
Niparuck P.
Saengboon S.
Limvorapitak W.
Silpsamrit P.
Prayongratana K.
Sriswasdi C.
Julamanee J.
Saelue P.
Sasakul A.
Jit-ueakul D.
Nakhakes C.
Tantiworawit A.
Rattarittamrong E.
Wanitpongpun C.
Kungwankiattichai S.
Owattanapanich W.
Chanswangphuwana C.
Polprasert C.
Piyajaroenkij T.
Niparuck P.
Saengboon S.
Limvorapitak W.
Silpsamrit P.
Prayongratana K.
Sriswasdi C.
Julamanee J.
Saelue P.
Sasakul A.
Jit-ueakul D.
Nakhakes C.
Tantiworawit A.
Author's Affiliation
Prince of Songkla University
Thammasat University
Siriraj Hospital
Faculty of Medicine, Chiang Mai University
Ramathibodi Hospital
Faculty of Medicine, Khon Kaen University
Faculty of Medicine, Chulalongkorn University
Phramongkutklao College of Medicine
Rajavithi Hospital
Chulabhorn Royal Academy
Vajira Hospital
Thammasat University
Siriraj Hospital
Faculty of Medicine, Chiang Mai University
Ramathibodi Hospital
Faculty of Medicine, Khon Kaen University
Faculty of Medicine, Chulalongkorn University
Phramongkutklao College of Medicine
Rajavithi Hospital
Chulabhorn Royal Academy
Vajira Hospital
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: FLT3-ITD mutations are among the most common genetic alterations in acute myeloid leukemia (AML) and are associated with poor clinical outcomes. However, data from low- and middle-income countries remain limited. This study aimed to investigate the prevalence, clinical characteristics, treatment patterns, and outcomes of adult AML patients with FLT3-ITD mutations in Thailand. Methods: We analyzed data from 360 adult patients with newly diagnosed AML, prospectively collected from 11 institutions nationwide between 2016 and 2023. FLT3-ITD mutational status, clinical features, response to therapy, and survival outcomes were compared between FLT3-ITD and FLT3-wild-type patients. Results: FLT3-ITD mutations were detected in 28.1% of patients. FLT3-ITD patients had higher white blood cell counts, bone marrow blast percentages, and NPM1 co-mutations compared to wild-type FLT3. Induction chemotherapy rates were similar, but FLT3 inhibitor use was nearly absent. Complete remission was achieved in 55.7% of FLT3-ITD patients versus 66.5% in wild-type FLT3. Median overall survival was significantly shorter in the FLT3-ITD group (8.8 vs. 13.2 months, p=0.039), while relapse-free survival was not significantly different. Multivariable analysis confirmed FLT3-ITD mutation as an independent predictor of poor overall survival. Conclusions: In this nationwide real-world study, FLT3-ITD AML was associated with inferior outcomes despite comparable induction therapy. Limited access to FLT3-targeted treatments and stem cell transplantation may contribute to these disparities. Our findings highlight the urgent need for expanding access to molecular testing and targeted therapies in resource-limited settings.